Revolution Medicines, Inc.(RVMD)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

RVMD Revolution Medicines, Inc.

交易中 09-02 09:31:39 EDT

211.05

+1.18

+0.56%

最高211.40	最低210.37	成交量2.47万
今开211.36	昨收209.87	日振幅0.49%
总市值452.36亿	流通市值388.33亿	总股本2.14亿
成交额521.95万	换手率0.01%	流通股本1.84亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"RVMD","market":"US","secType":"STK","nameCN":"Revolution Medicines, Inc.","latestPrice":211.05,"timestamp":1788355891597,"preClose":209.87,"halted":0,"volume":24712,"delay":0,"changeRate":0.005622528231762552,"floatShares":184000000,"shares":214336418,"eps":-8.921187,"marketStatus":"交易中","change":1.18,"latestTime":"09-02 09:31:39 EDT","open":211.36,"high":211.4,"low":210.3675,"amount":5219546.80984,"amplitude":0.00492,"askPrice":212,"askSize":604,"bidPrice":210.95,"bidSize":101,"shortable":3,"etf":0,"ttmEps":-8.921187,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1788379200000},"marketStatusCode":2,"adr":0,"listingDate":1581570000000,"exchange":"NASDAQ","adjPreClose":209.87,"preHourTrading":{"tag":"盘前","latestPrice":211.52,"preClose":209.87,"latestTime":"09:29 EDT","volume":2491,"amount":524414.68616,"timestamp":1788355799982,"change":1.65,"changeRate":0.007862,"amplitude":0.033926},"postHourTrading":{"tag":"盘后","latestPrice":210.7356,"preClose":209.87,"latestTime":"19:58 EDT","volume":18272,"amount":3833966.1152,"timestamp":1788307081096,"change":0.8656,"changeRate":0.004124,"amplitude":0.014294},"volumeRatio":1.853876,"impliedVol":0.4709,"impliedVolPercentile":0.0714},"requestUrl":"/m/hq/s/RVMD","defaultTab":"news","newsList":[{"id":"1106079427","title":"异动解读｜Revolution Medicines盘中下跌5.02%，新药获批利好兑现后遭获利了结","url":"https://stock-news.laohu8.com/highlight/detail?id=1106079427","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1106079427?lang=zh_cn&edition=full","pubTime":"2026-08-28 22:31","pubTimestamp":1787927476,"startTime":"0","endTime":"0","summary":"8月28日，Revolution Medicines盘中下跌5.02%，报210.055美元/股，成交额1.04亿美元。消息面上，FDA于8月26日正式批准公司旗下首款RAS靶向口服药Rasonque上市，用于治疗转移性胰腺癌，将患者中位生存期从6.7个月延长至13.2个月。该药年费超47.5万美元，30天疗程批发价39,800美元。然而，公司股价年内累计涨幅已超166%，市场此前已充分预期获批，属典型\"利好兑现\"式回调。此外，当日生物科技板块整体承压，Moderna跌5.72%、BioNTech跌8.15%，行业情绪偏弱亦加剧跌势。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"新药获批利好兑现，Revolution Medicines回落","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RVMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662061828","title":"美国FDA批准胰腺癌突破性药物 独立药企Revolution Medicines迎里程碑","url":"https://stock-news.laohu8.com/highlight/detail?id=2662061828","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662061828?lang=zh_cn&edition=full","pubTime":"2026-08-28 18:15","pubTimestamp":1787912149,"startTime":"0","endTime":"0","summary":"Revolution Medicines历时近十年持续攻关，在500人规模临床试验中获得积极数据，最终获得监管批准。为完成交易，戈德史密斯与Warp Drive最大股东赛诺菲协商，将后者持有的Warp Drive多数股权置换为Revolution Medicines的部分股权，最终达成协议。在正式获批前，美国食品药品管理局已通过同情用药项目允许Revolution Medicines提前约四个月向患者分发药物，截至获批时已有超过2000名患者纳入该项目。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-08-28/doc-inipwhrt5845666.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina_us","symbols":["IE00B4R5TH58.HKD","IE00BJT1NW94.SGD","BK4139","LU0889565916.HKD","LU0109394709.USD","CANC","LU0320765992.SGD","IE0009354923.USD","IDNA","IE00BJJMRZ35.SGD","IE0009355771.USD","LABU","IE0002141913.USD","RVMD","IE00B2B36J28.USD","IE00BFTCPJ56.SGD","PTH","BBH","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662722025","title":"杰富瑞：将Revolution Medicines目标价从242美元上调至270美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2662722025","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662722025?lang=zh_cn&edition=full","pubTime":"2026-08-27 11:50","pubTimestamp":1787802605,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0889565916.HKD","IE00BJJMRZ35.SGD","IE0002141913.USD","LU0109394709.USD","BK4139","IE00B4R5TH58.HKD","LU0320765992.SGD","IE00BFTCPJ56.SGD","IE00BJT1NW94.SGD","PTH","BBH","RVMD","UDN","IE0009355771.USD","UUP","IE0009354923.USD","CANC","IDNA","IE00B2B36J28.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662741140","title":"胰腺癌治疗迎历史性突破！FDA批准RevMed靶向新药，预计2032年销售超90亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2662741140","media":"华尔街见闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662741140?lang=zh_cn&edition=full","pubTime":"2026-08-27 03:59","pubTimestamp":1787774360,"startTime":"0","endTime":"0","summary":"$Revolution Medicines$旗下胰腺癌新药daraxonrasib获得$美国食品$药品监督管理局批准上市，成为首款针对该疾病关键分子致病机制的靶向药物，标志着胰腺癌治疗领域多年来最重要的突破之一。该药以商品名Rasonque上市，年标价超47.5万美元。消息公布后，RevMed股价上涨，截至发稿盘中上涨2.5%，今年以来累计涨幅已超过一倍，公司市值突破450亿美元。华尔街分析师预测，该药2032年销售额有望超过90亿美元。","market":"us","thumbnail":"https://static.tigerbbs.com/cf00d3e001bd81b11eb9b57bd44b96ab","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/cf00d3e001bd81b11eb9b57bd44b96ab"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3780372","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"胰腺癌治疗迎历史性突破！FDA批准RevMed靶向新药，预计2032年销售超90亿美元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4588","RVMD"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1164882019","title":"Revolution Medicines旗下Rasonque美国正式上市，30天疗程批发采购价39,800美元——电话会议披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1164882019","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1164882019?lang=zh_cn&edition=full","pubTime":"2026-08-27 01:57","pubTimestamp":1787767031,"startTime":"0","endTime":"0","summary":"Revolution Medicines公司日前宣布，其研发的Rasonque药物现已在美国市场正式商业化供应。这款产品的批发采购成本定为39,800美元，对应30天的用药剂量。值得注意的是，此次上市定价反映了Rasonque在精准肿瘤治疗领域的差异化价值主张。从商业角度看，这一价格策略也释放出Revolution Medicines对其产品竞争力的强烈信心。分析人士指出，随着Rasonque正式进入流通渠道，相关供应链与市场准入工作已全面启动。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765992.SGD","LU0889565916.HKD","IE0002141913.USD","IE0009354923.USD","BK4139","LU0109394709.USD","IDNA","IE0009355771.USD","IE00B4R5TH58.HKD","IE00BFTCPJ56.SGD","BBH","CANC","IE00BJJMRZ35.SGD","RVMD","IE00BJT1NW94.SGD","IE00B2B36J28.USD","PTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156385670","title":"美国FDA批准Revolution Medicines旗下Rasonque™（Daraxonrasib）上市，开创转移性胰腺癌广谱Ras靶向治疗先河","url":"https://stock-news.laohu8.com/highlight/detail?id=1156385670","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1156385670?lang=zh_cn&edition=full","pubTime":"2026-08-27 01:00","pubTimestamp":1787763644,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局正式批准了Revolution Medicines研发的Rasonque——这标志着全球首款针对转移性胰腺癌的广谱Ras靶向药物成功问世。此举不仅为晚期胰腺癌患者带来了全新的治疗选项，更在肿瘤精准医疗领域树立起一座重要的里程碑。此次获批，无疑将深刻影响胰腺癌治疗的现有格局。对于广大深受胰腺癌困扰的患者群体而言，Rasonque的上市，无疑为他们与病魔的抗争增添了一件有力武器。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CANC","IE00B2B36J28.USD","IE00B4R5TH58.HKD","BBH","IE0009354923.USD","IE00BJT1NW94.SGD","LU0109394709.USD","IE0002141913.USD","IDNA","IE00BJJMRZ35.SGD","IE0009355771.USD","LU0889565916.HKD","BK4139","PTH","LU0320765992.SGD","IE00BFTCPJ56.SGD","RVMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662482997","title":"Revolution Medicines的胰腺癌药物 Daraxonrasib已获得美国监管机构的批准，这是首款针对胰腺","url":"https://stock-news.laohu8.com/highlight/detail?id=2662482997","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662482997?lang=zh_cn&edition=full","pubTime":"2026-08-26 23:14","pubTimestamp":1787757271,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IDNA","BK4139","IE0009354923.USD","IE00BFTCPJ56.SGD","IE00BJT1NW94.SGD","IE0002141913.USD","CANC","BBH","IE00B4R5TH58.HKD","LU0109394709.USD","LU0889565916.HKD","IE0009355771.USD","IE00BJJMRZ35.SGD","LU0320765992.SGD","RVMD","IE00B2B36J28.USD","PTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114413981","title":"异动解读｜Revolution Medicines盘中下跌5.34%，报200.13美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1114413981","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1114413981?lang=zh_cn&edition=full","pubTime":"2026-08-26 22:45","pubTimestamp":1787755511,"startTime":"0","endTime":"0","summary":"8月26日，Revolution Medicines盘中下跌5.34%，报200.13美元/股，成交额8347.87万美元。Revolution Medicines所在的生物科技行业中，个股中，Moderna下跌5.87%，安进下跌0.36%，艾伯维公司下跌1.38%，吉利德科学持平，Natera上涨1.13%。Revolution Medicines是一家临床阶段的精准肿瘤学公司，专注于开发靶向疗法以抑制RAS成瘾癌症的前沿靶点，拥有先进的基于结构的药物发现能力。公司过去52周累计涨幅超470%，近期股价处于历史高位区间。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RVMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123958766","title":"异动解读｜Revolution Medicines盘中上涨5.05%，与百济神州达成RAS抑制剂合作持续催化","url":"https://stock-news.laohu8.com/highlight/detail?id=1123958766","media":"行情直击","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1123958766?lang=zh_cn&edition=full","pubTime":"2026-08-18 01:35","pubTimestamp":1786988128,"startTime":"0","endTime":"0","summary":"8月18日，Revolution Medicines盘中上涨5.05%，报214.4美元/股，成交额1.42亿美元，延续近期强势上行趋势。消息面上，公司于8月10日宣布与百济神州达成多方面合作协议，涵盖临床联合开发与区域商业化授权。根据协议，百济神州获得公司旗下daraxonrasib、zoldonrasib、elironrasib及RMC-5127四款临床阶段RAS抑制剂在部分亚洲市场的独家开发及商业化权益，并将出资推动一项全球注册性III期研究。其中daraxonrasib在胰腺癌三期试验中中位总生存期达13.2个月，远超化疗的6.7个月，zoldonrasib已获FDA突破性疗法认定。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RVMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658161961","title":"市值超4800亿元的药企股价涨逾4%: 这款“癌王”突破疗法要来中国了","url":"https://stock-news.laohu8.com/highlight/detail?id=2658161961","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658161961?lang=zh_cn&edition=full","pubTime":"2026-08-11 12:48","pubTimestamp":1786423687,"startTime":"0","endTime":"0","summary":"8月11日上午，百济神州（ONC.US、06160.HK、688235.SH）A股以及港股股价涨幅超过4%，其中A股市值达到4820亿元。盘面上，公司前一晚与RevolutionMedicines宣布达成临床开发及区域商业化合作。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608113837721960.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608113837721960.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0124384867.USD","LU1854103824.USD","RVMD","IE0009354923.USD","LU1251922891.USD","LU0320765992.SGD","LU2298322129.HKD","IE00BJJMRZ35.SGD","LU1720051017.SGD","LU1770034418.SGD","BK1583","LU1854104046.USD","IE00B2B36J28.USD","LU1978683503.SGD","LU0588546209.SGD","LU0724618433.USD","06160","IE00BJT1NW94.SGD","IE0002141913.USD","LU1548497426.USD","688235","KURE","BK0239","LU1861219969.SGD","BK1588","LU2357305700.SGD","BK4512","IE0009355771.USD","BK4141","CANC","IE00BZ199S13.USD","LU0348723411.USD","LU1720051108.HKD","BK4605","LU0889565916.HKD","LU1861215975.USD","IE00BFMHRM44.USD","LU2360107325.USD","LU0109394709.USD","LU1861214812.USD","BK4139","IE00BD6J9T35.USD","BK4585","BBH","LU1983260115.SGD","IDNA","ON","PTH","IE00BFTCPJ56.SGD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658965691","title":"港股异动 | 百济神州(06160)早盘涨超4% 与Revolution Medicines达成临床合作 将加快RAS赛道开发进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2658965691","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658965691?lang=zh_cn&edition=full","pubTime":"2026-08-11 09:42","pubTimestamp":1786412546,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，百济神州早盘涨超4%，截至发稿，涨2.72%，报219港元，成交额2.97亿港元。消息面上，8月10日，据百济神州官微消息，公司与Revolution Medicines,Inc.宣布达成一项多方面合作协议。根据协议，双方将开展临床合作，共同评估百济神州部分处于临床阶段的肿瘤候选药物与Revolution Medicines四款临床阶段RAS抑制剂中任意一款或多款药物的联合治疗方案;同时，双方还达成区域授权协议，百济神州获得Revolution Medicines上述候选药物在部分亚洲市场的独家开发及商业化权益。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1478320.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1588","LU1770034418.SGD","LU2328871848.SGD","688235","BBH","BK4588","LU0109394709.USD","IE0009354923.USD","LU0828237510.HKD","BK4139","LU1969619763.USD","LU1251922891.USD","KURE","CANC","LU1303224171.USD","BK1161","IDNA","LU0320765992.SGD","IE00B4R5TH58.HKD","BK4526","IE00BJT1NW94.SGD","IE0002141913.USD","IE00B2B36J28.USD","06160","LU0228659784.USD","RVMD","LU0889565916.HKD","KCAI","VXUS","BK1583","LU1719994722.HKD","IE00BFTCPJ56.SGD","IE00BJJMRZ35.SGD","LU0588546209.SGD","BK1500","ONC","PTH","IE0009355771.USD","LU0307460666.USD","BK0239","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658950149","title":"百济神州与Revolution Medicines达成临床开发及区域商业化合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2658950149","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658950149?lang=zh_cn&edition=full","pubTime":"2026-08-11 07:40","pubTimestamp":1786405224,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BBH","IE00B4R5TH58.HKD","RVMD","CANC","LU0889565916.HKD","BK4526","IE0009354923.USD","IE00B2B36J28.USD","ONC","IE00BFTCPJ56.SGD","PTH","IE0002141913.USD","IE00BJJMRZ35.SGD","LU0109394709.USD","IE00BJT1NW94.SGD","BK4139","IDNA","BK4588","BK4585","IE0009355771.USD","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658950539","title":"百济神州与Revolution Medicines宣布合作；甘李药业宣布减肥新药海外BD | 医药早参","url":"https://stock-news.laohu8.com/highlight/detail?id=2658950539","media":"每日经济新闻","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658950539?lang=zh_cn&edition=full","pubTime":"2026-08-11 07:01","pubTimestamp":1786402877,"startTime":"0","endTime":"0","summary":"丨2026年8月11日星期二丨NO.1百济神州与RevolutionMedicines宣布达成临床开发及区域商业化合作8月10日，百济神州宣布与全球专注癌症药物研发的生物科技公司RevolutionMedicines达成一项多方面合作协议，涵盖临床联合开发与区域商业化授权两大核心板块，旨在加速RAS驱动型癌症的创新疗法研发与市场落地。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608113837029212.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608113837029212.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0109394709.USD","IDNA","BK1588","IE00BJT1NW94.SGD","BK0239","LU1719994722.HKD","09939","LU0588546209.SGD","159938","603087","IE00B2B36J28.USD","LU2328871848.SGD","LU1251922891.USD","ONC","IE00BFTCPJ56.SGD","KURE","BK4526","LU0320765992.SGD","688235","CANC","IE00BJJMRZ35.SGD","BK1583","LU0228659784.USD","BBH","BK4139","06160","BK4585","IE00B4R5TH58.HKD","BK1161","IE0002141913.USD","BK1515","LU1770034418.SGD","LU1303224171.USD","RVMD","IE0009354923.USD","LU1969619763.USD","LU0307460666.USD","LU0889565916.HKD","BK4588","PTH","LU0828237510.HKD","BK1574","BK1500","BD","IE0009355771.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189831237","title":"百济神州获Revolution Medicines四大资产在选定亚洲市场的独家授权","url":"https://stock-news.laohu8.com/highlight/detail?id=1189831237","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1189831237?lang=zh_cn&edition=full","pubTime":"2026-08-10 18:05","pubTimestamp":1786356339,"startTime":"0","endTime":"0","summary":"百济神州（Beone Medicines Ltd.）宣布，已获得Revolution Medicines, Inc.旗下四项核心资产在特定亚洲市场的独家权利。这一战略合作，标志着百济神州在亚洲关键区域的布局进一步深化。\n依据协议，百济神州将独家享有Revolution Medicines这四款创新药物在部分亚洲国家和地区的开发、商业化权益。此举不仅丰富了百济神州的肿瘤产品管线，也为其在亚洲市场的竞争力增添了强劲动力。交易的财务细节尚未披露，但市场分析人士普遍认为，此举对双方而言都是互利共赢的明智选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BJT1NW94.SGD","BK0239","IE0009354923.USD","LU0109394709.USD","IE00BJJMRZ35.SGD","BBH","RVMD","688235","IE00BFTCPJ56.SGD","IE0009355771.USD","IE00B4R5TH58.HKD","PTH","IDNA","LU0889565916.HKD","BK4139","CANC","IE0002141913.USD","IE00B2B36J28.USD","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142470173","title":"百济神州与Revolution Medicines合作：里程碑付款与分级版税权益","url":"https://stock-news.laohu8.com/highlight/detail?id=1142470173","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1142470173?lang=zh_cn&edition=full","pubTime":"2026-08-10 18:04","pubTimestamp":1786356295,"startTime":"0","endTime":"0","summary":"百济神州（Beone Medicines Ltd.）与Revolution Medicines, Inc.已达成合作，根据协议，双方将在合作区域内享有获得里程碑付款及分级版税的权利。这一安排标志着两家公司在共同开发与商业化方面迈出了重要一步，为各自带来了潜在的经济收益与战略协同。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109394709.USD","BK0239","LU0889565916.HKD","IE0002141913.USD","688235","IE00BJJMRZ35.SGD","IE00BFTCPJ56.SGD","BK4139","BBH","IE00B4R5TH58.HKD","IE00B2B36J28.USD","CANC","RVMD","IE0009354923.USD","IE00BJT1NW94.SGD","IDNA","PTH","LU0320765992.SGD","IE0009355771.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657147096","title":"根据美国证券交易委员会文件披露，谷歌母公司Alphabet Inc.将其持有Revolution Medicines I","url":"https://stock-news.laohu8.com/highlight/detail?id=2657147096","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657147096?lang=zh_cn&edition=full","pubTime":"2026-08-07 18:07","pubTimestamp":1786097238,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4527","LU1201861249.SGD","IE00B19Z9505.USD","BK4574","LU0976567544.SGD","IE00BHPRN162.USD","IE00BJJMRZ35.SGD","BK4533","IE0034235303.USD","IE00BMPRXQ63.HKD","LU2125909593.SGD","LU1670628061.USD","IE00BDRTCR15.USD","LU1823568750.SGD","LU0203347892.USD","LU1316542783.SGD","GOOGL","LU1974910355.USD","IE00BMPRXR70.SGD","LU0784385840.USD","LU1435385759.SGD","LU0345774631.USD","LU2860962120.EUR","LU2111349929.HKD","LU1323610961.USD","XDAT","IE00BDCRKT87.USD","LU0354030438.USD","LU0957808578.USD","LU1003077747.HKD","LU1202635105.USD","GOOW","LU1551013342.USD","IE0002270589.USD","LU1629891620.HKD","BK4576","LU2098885051.SGD","SG9999014906.USD","LU2102340556.USD","BK4566","IE00B4R5TH58.HKD","GOU","LU1699723380.USD","LU2357305700.SGD","ILDR","LU2250418816.HKD","IE00B1BXHZ80.USD","IE000MB6IJN5.SGD","BK4139","LU2168564149.EUR","LU0106261372.USD","LU2430703095.HKD","LU2362540622.SGD","LU2404859667.USD","SG9999015358.SGD","SNPE","LU2211815571.USD","IE00B19Z3581.USD","LU0444973449.USD","LU2236285917.USD","LU0742534661.SGD","LU2213496289.HKD","LU0528227936.USD","LU0070217475.USD","LU1674673428.USD","LU0048584097.USD","LU1989764748.USD","LU1400636491.USD","HK0000304805.HKD","LU0943347566.SGD","LU2360106780.USD","LU1720051017.SGD","RVMD","LU2462591277.SGD","IE0034235295.USD","LU0174119429.USD","LU2125909247.SGD","LU0496365809.HKD","LU1868837136.USD","LU0170899867.USD","LU0052756011.USD","LU0203345920.USD","LU1196500208.SGD","LU2092937148.SGD","CQTM","LU0256863811.USD","IE0034235188.USD","LU0154236417.USD","LU0889566641.SGD","LU1935042488.USD","LU0211327993.USD","SG9999014914.USD","LU1674673691.USD","GGLL","LU2462157665.USD","LU0251131958.USD","LU0545039389.USD","SG9999014575.USD","LU0107464264.USD","LU0314106906.USD","LU1066051811.HKD","LU1267930490.SGD","LU2999663052.SGD","LU1301847155.USD","GXPC","LU1145028129.USD","LU0708995401.HKD","LU2168563687.JPY","LU0289961442.SGD","LU1988902786.USD","LU0348723411.USD","LU1066053197.SGD","LU1935043023.USD","GB00B4QBRK32.GBP","BK4585","LU2462591350.SGD","SG9999017495.SGD","LU0345768740.USD","LU2089283258.USD","LU0820561909.HKD","SG9999014567.USD","LU2491050071.SGD","LU2023250504.SGD","LU1917777945.USD","LU0265550359.USD","IE0004091025.USD","IE00BK4W5M84.HKD","LU0477156953.USD","SG9999015945.SGD","HK0000819398.USD","LU1645745479.HKD","SGXZ81514606.USD","LU1935042991.SGD","LU1267930730.SGD","IE0009355771.USD","BK4538","CANC","OGIG","LU2065171402.SGD","SG9999018857.SGD","IE00BJT1NW94.SGD","LU1571399168.USD","LU1066051225.USD","IE00BLSP4452.SGD","LU0417517546.SGD","LU0323591593.USD","LU2237438978.USD","LU0472753341.HKD","LU0345770308.USD","LU2023250330.USD","BK4602","LTL","LU1551013425.SGD","LU0130518102.USD","LU0069063385.USD","LU1430594728.SGD","LU2471134879.HKD","LU1989772923.USD","SGXZ99366536.SGD","LU0823434583.USD","BK4612","IE00BJTD4V19.USD","LU0683600562.USD","LU2404859741.USD","LU0128525689.USD","LU1894683348.USD","LU1303367103.USD","LU2065171311.SGD","BK4592","IE00B19Z3B42.SGD","LU2471134796.USD","LU0225283273.USD","LU1670756490.USD","IE00BKPKM429.USD","LU2756315664.SGD","LU0138981039.USD","LU2097344357.USD","LU1791710582.SGD","LU2028103732.USD","BK4550","LU2087625088.SGD","LU1366333091.USD","LU1923623000.USD","LU2264538146.SGD","IE00BKVL7J92.USD","LU1267930573.SGD","SG9999018865.SGD","LU0476273544.USD","BK4561","LU0784384876.USD","LU2954938101.SGD","SGXZ51526630.SGD","LU2471134952.CNY","LU0128525929.USD","LU0289739343.SGD","LU0158827948.USD","LU0109394709.USD","LU0672654240.SGD","LU0267386448.USD","LU1496350171.SGD","VOX","LU2023251221.USD","LU2750360997.AUD","FCOM","LU0980610538.SGD","LU0868494708.USD","LU2168564065.EUR","LU1400636574.HKD","LU0511384066.AUD","LU1084165304.USD","GB00B4LPDJ14.GBP","LU0061474705.USD","BK4598","LU2505996509.AUD","LU0175139822.USD","LU0048573561.USD","IDNA","BK4581","LU1670627923.USD","IE00BJTD4N35.SGD","LU0994945656.USD","IE00B7SZLL34.SGD","LU2592432038.USD","LU1804176565.USD","LU1548497426.USD","LU2746668974.SGD","XLC","IE0002141913.USD","LU2168564222.USD","IE00BK4W5L77.USD","LU0426417589.USD","SG9999014559.SGD","BK4573","IE000WAW04H5.SGD","LU2065170008.USD","IE00BFMHRM44.USD","LU0234572021.USD","LU1852331112.SGD","LU0310800965.SGD","LU2087621335.USD","BK4503","LU2471134523.USD","LU0640476718.USD","LU0957791311.USD","LU1868836591.USD","LU2106854487.HKD","LU2242649171.HKD","GOOP","LU2360032135.SGD","LU0882574139.USD","SG9999015978.USD","LU0889565916.HKD","LU0096364046.USD","LU1232071149.USD","LU0011850046.USD","LU0689472784.USD","LU1506573853.SGD","LU2433249047.HKD","LU2505996681.GBP","LU1951198990.SGD","LU0477156797.USD","LU0494093205.USD","LU0648001328.SGD","IE00BN8TJ469.HKD","LU0310800379.SGD","LU1935043536.SGD","LU1642822529.SGD","LU1267930813.SGD","BK4532","LU1244550577.SGD","LU2089284900.SGD","LU2097344431.USD","LU0130517989.USD","LU0342679015.USD","LU1043141123.HKD","LU0466842654.USD","LU1989764664.SGD","LU0784383803.USD","IE00BSNM7G36.USD","SG9999015952.SGD","LU0157215616.USD","LU2065169927.USD","LU1868836757.USD","LU1400636657.SGD","LU0061474960.USD","LU0985320562.USD","LU2430703251.USD","IE0009354923.USD","LU1923622614.USD","LU1221951129.SGD","LU0211328371.USD","LU2326559502.SGD","LU0124676726.USD","SGXZ31699556.SGD","LU0964807845.USD","LU2097829019.USD","LU2403377893.USD","LU2077746001.SGD","LU0096362180.USD","BK4514","LU1121112475.USD","LU0784385170.HKD","LU1267930227.SGD","LU1429558221.USD","IE00BMPRXN33.USD","IE00BJLML261.HKD","LU0251142724.SGD","LU0823434740.USD","LU1778281490.HKD","LU2746668461.USD","LU2750360641.GBP","SG9999014542.SGD","PTH","LU1201861165.SGD","LU2265009873.SGD","BK4588","LU0127658192.USD","LU0029864427.USD","LU0320765059.SGD","LU1880398471.USD","METV","IE000F7OJYX1.SGD","SKYY","LU0210533765.USD","LU2125154935.USD","LU2054465674.USD","LU1989772840.SGD","LU0353189763.USD","LU0149725797.USD","LU0942090050.USD","LU0553294199.USD","LU1244550221.USD","IE000SO60NU8.SGD","LU1244550494.USD","LU0211326755.USD","LU1718418525.SGD","SG9999014898.SGD","EFIV","LU0289960550.SGD","LU0949170426.SGD","HK0000304797.USD","LU0234570918.USD","LU1064131342.USD","LU2191332357.HKD","LU0689626769.HKD","LU0792757196.USD","LU0820561818.USD","LU0557290698.USD","LU0648000940.SGD","LU2420271590.USD","IE00BWXC8680.SGD","LU0130102774.USD","LU0642271901.SGD","LU0949170772.SGD","TRUC","LU0070302665.USD","LU0353189680.USD","LU1116320737.USD","IE000BZT7R73.USD","LU1116320901.HKD","LU0130103400.USD","LU1894683264.USD","GGLS","LU1235294995.USD","LU1261432733.SGD","LU1868837300.USD","LU0345774391.USD","LU0061475181.USD","LU0256863902.USD","LU1880398554.USD","LU2602419157.SGD","LU1032955483.USD","HK0000914660.USD","LU2247934214.USD","LU0215105999.USD","IE00BLSP4239.USD","LU0302445910.USD","BK4534","LU0211331839.USD","LU0310799852.SGD","BK4077","LU1066051498.USD","LU0211326839.USD","SG9999000418.SGD","IE00BQXX3C00.GBP","LU0820562030.AUD","BBH","IE00BZ1G4Q59.USD","SG9999015986.USD","IE00BD6J9T35.USD","LU2242650005.HKD","LU0345768153.USD","IE0001KFT4U8.USD","LU0787776722.HKD","IE0000B7K699.USD","IE00BQXX3F31.USD","HK0000532082.HKD","LU2417539215.USD","IE00BYXW3230.USD","LU0426412945.USD","IE00BBT3K403.USD","LU0077335932.USD","LU0265550946.USD","SG9999015341.SGD","LU0251132253.USD","LU2362541513.USD","LU2491049909.HKD","BK4543","SGXZ44715902.SGD","IE00B1XK9C88.USD","LU1720051108.HKD","LU0056508442.USD","LU1815336760.USD","LU1585245621.USD","LU0708994859.HKD","LU1043141396.HKD","LU0094547139.USD","IE00B2B36J28.USD","LU2756315318.SGD","LU1496350502.SGD","LU2023250843.SGD","LU0345770993.USD","LU0080751232.USD","LU1221951046.USD","LU2168564495.EUR","LU2244417387.USD","LU1815333072.USD","CMAG","LU0314104364.USD","GOOY","LU0316494557.USD","LU0187121727.USD","LU0198837287.USD","LU1935042215.USD","LU0354030511.USD","LU0109391861.USD","LU0143551892.USD","LU0057025933.USD","LU2362541273.HKD","LU2491050154.USD","IE00BFTCPJ56.SGD","LU2381873111.SGD","LU1633808545.USD","LU2063271972.USD","LU0738911758.USD","LU0320765992.SGD","LU0823421416.USD","LU1119994496.HKD","LU1059921491.USD","LU0097036916.USD","IE00B19Z8W00.USD","IE00BQXX3D17.EUR","LU0661504455.SGD","LU1280957306.USD","LU1803068623.USD","LU0690374615.EUR","IE0004086264.USD","LU0345769631.USD","LU0320765489.SGD","LU2092627202.USD","LU1046421795.USD","HK0000914686.HKD","LU0276348264.USD","LU2271345857.HKD","GOOX","LU2125154778.USD","LU0006306889.USD","LU0690374961.EUR","LU0208291251.USD","LU0158827781.USD","LU1153585028.USD","LU1951200564.SGD","LU0444971666.USD","LU2456880835.USD","SG9999014880.SGD","LU0312595415.SGD","LU1868836914.USD","LU0868494617.USD","LU0823421333.USD","LU1914381329.SGD","LU1839511570.USD","LU0345769128.USD","LU2430703178.SGD","BK4579","LU2275660780.HKD","IE00B19Z8X17.USD","IE00BKDWB100.SGD","LU1791710400.SGD","LU1366192091.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125314601","title":"异动解读｜Revolution Medicines盘中上涨5.23%，FDA受理新药申请叠加财报前市场预期升温","url":"https://stock-news.laohu8.com/highlight/detail?id=1125314601","media":"行情直击","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1125314601?lang=zh_cn&edition=full","pubTime":"2026-08-05 00:35","pubTimestamp":1785861308,"startTime":"0","endTime":"0","summary":"8月5日，Revolution Medicines盘中上涨5.23%，报191.99美元/股，成交额9810.16万美元。消息面上，FDA此前已正式受理公司核心管线药物Daraxonrasib用于既往治疗过的转移性胰腺癌的新药上市申请（NDA），标志关键监管里程碑。同时欧洲药品管理局亦启动分阶段审评加速评估。Wedbush将目标价上调至192.10美元并维持跑赢大盘评级。此外，公司当日盘后将发布季度财报，市场对RAS靶向药物商业化前景预期持续升温，多重催化剂共振推动股价上行。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RVMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131945806","title":"异动解读｜Revolution Medicines盘中上涨5.02%，FDA受理胰腺癌新药上市申请叠加投行上调目标价","url":"https://stock-news.laohu8.com/highlight/detail?id=1131945806","media":"行情直击","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1131945806?lang=zh_cn&edition=full","pubTime":"2026-07-31 03:12","pubTimestamp":1785438771,"startTime":"0","endTime":"0","summary":"7月31日，Revolution Medicines盘中上涨5.02%，报190.0美元/股，成交额2.3亿美元。消息面上，FDA已正式受理公司提交的Daraxonrasib新药上市申请，用于治疗既往接受过治疗的转移性胰腺癌患者，标志着药物进入实质性审评阶段。同时，Wedbush将公司目标价由181美元上调至192.10美元，维持\"跑赢大盘\"评级，分析师共识均价达203.85美元。此前该药物三期试验数据显示，中位总生存期延长一倍至13.2个月，欧洲药品管理局亦已启动分阶段加速审评，全球商业化前景进一步明朗。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RVMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117561795","title":"异动解读｜Revolution Medicines盘中上涨5.06%，核心药物NDA获FDA正式受理","url":"https://stock-news.laohu8.com/highlight/detail?id=1117561795","media":"行情直击","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1117561795?lang=zh_cn&edition=full","pubTime":"2026-07-23 22:24","pubTimestamp":1784816691,"startTime":"0","endTime":"0","summary":"7月23日，Revolution Medicines盘中上涨5.06%，报192.3美元/股，成交额1.06亿美元。消息面上，FDA已正式受理公司核心候选药物Daraxonrasib的新药上市申请，适应症为既往接受过治疗的转移性胰腺癌。该受理标志着关键监管里程碑，意味着FDA已启动实质性审评流程。同日，Wedbush将公司目标价从181美元上调至192.10美元，维持\"跑赢大盘\"评级。Revolution Medicines成立于2014年，是一家临床阶段精准肿瘤学公司，专注于开发靶向RAS成瘾癌症的创新疗法。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RVMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178535518","title":"Revolution Medicines新药Daraxonrasib获FDA受理，用于既往治疗过的转移性胰腺癌","url":"https://stock-news.laohu8.com/highlight/detail?id=1178535518","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1178535518?lang=zh_cn&edition=full","pubTime":"2026-07-23 04:06","pubTimestamp":1784750800,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局（FDA）已正式受理Revolution Medicines, Inc.提交的新药上市申请（NDA），该申请旨在寻求批准其候选药物Daraxonrasib用于治疗既往接受过治疗的转移性胰腺癌患者。\n这一受理标志着该药物研发进程中的一个关键监管里程碑，意味着FDA已认定申请材料完整，并已启动实质性的审评流程。胰腺癌，尤其是转移性疾病，长期以来预后不佳，治疗选择有限，因此这一新疗法的审评进展备受业界关注。\n公司股价在消息公布后反应积极，市场正密切关注后续的审评时间表以及可能的批准前景。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTH","IE00B2B36J28.USD","RVMD","BK4139","IE00BFTCPJ56.SGD","IE00BJJMRZ35.SGD","IE0009354923.USD","IE0009355771.USD","IE00BJT1NW94.SGD","IDNA","LU0889565916.HKD","IE0002141913.USD","CANC","IE00B4R5TH58.HKD","LU0320765992.SGD","LU0109394709.USD","BBH"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.revmed.com;ir.revmed.com","stockEarnings":[{"period":"1week","weight":-0.0071},{"period":"1month","weight":0.1191},{"period":"3month","weight":0.3454},{"period":"6month","weight":1.1063},{"period":"1year","weight":4.5273},{"period":"ytd","weight":1.6349}],"compareEarnings":[{"period":"1week","weight":-0.0054},{"period":"1month","weight":0.0197},{"period":"3month","weight":0.01},{"period":"6month","weight":0.1181},{"period":"1year","weight":0.181},{"period":"ytd","weight":0.1171}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Revolution Medicines, Inc.成立于2014年10月，是特拉华州的一家公司。该公司是一家临床阶段的精准肿瘤学公司，专注于开发靶向疗法，以抑制RAS成瘾癌症的前沿靶点。该公司拥有先进的基于结构的药物发现能力，其基础是深厚的化学生物学和癌症药理学知识以及创新的专有技术，能够创造适合非常规结合位点的小分子。该公司对癌症的遗传驱动因素和适应性耐药机制的了解，加上强大的药物发现和药物化学能力，指导建立了一个针对RAS通路和相关通路中的关键信号节点的深层管道。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.034782},{"month":2,"riseRate":0.666667,"avgChangeRate":0.00452},{"month":3,"riseRate":0.428571,"avgChangeRate":-0.031822},{"month":4,"riseRate":0.714286,"avgChangeRate":0.114077},{"month":5,"riseRate":0.428571,"avgChangeRate":-0.015463},{"month":6,"riseRate":0.857143,"avgChangeRate":0.063598},{"month":7,"riseRate":0.571429,"avgChangeRate":-0.000417},{"month":8,"riseRate":0.714286,"avgChangeRate":0.065126},{"month":9,"riseRate":0.571429,"avgChangeRate":0.035689},{"month":10,"riseRate":0.666667,"avgChangeRate":0.019949},{"month":11,"riseRate":0.833333,"avgChangeRate":0.188424},{"month":12,"riseRate":0.5,"avgChangeRate":-0.027192}],"exchange":"NASDAQ","name":"Revolution Medicines, Inc.","nameEN":"Revolution Medicines, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Revolution Medicines, Inc.(RVMD)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Revolution Medicines, Inc.(RVMD)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Revolution Medicines, Inc.,RVMD,Revolution Medicines, Inc.股票,Revolution Medicines, Inc.股票老虎,Revolution Medicines, Inc.股票老虎国际,Revolution Medicines, Inc.行情,Revolution Medicines, Inc.股票行情,Revolution Medicines, Inc.股价,Revolution Medicines, Inc.股市,Revolution Medicines, Inc.股票价格,Revolution Medicines, Inc.股票交易,Revolution Medicines, Inc.股票购买,Revolution Medicines, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Revolution Medicines, Inc.(RVMD)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Revolution Medicines, Inc.(RVMD)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}